Tadashi Handa1, Ayaka Katayama1, Takehiko Yokobori2, Arito Yamane3, Jun Horiguchi4, Reika Kawabata-Iwakawa3, Susumu Rokudai3, Pinjie Bao5, Navchaa Gombodorj3, Bolag Altan6, Kyoichi Kaira6, Takayuki Asao7, Hiroyuki Kuwano4, Masahiko Nishiyama2,3, Tetsunari Oyama1. 1. Department of Diagnostic Pathology, Gunma University, Graduate School of Medicine, Maebashi, Japan. 2. Research Program for Omics-Based Medical Science, Division of Integrated Oncology Research, Gunma University Initiative for Advanced Research (GIAR), Maebashi, Japan. 3. Department of Molecular Pharmacology and Oncology, Gunma University, Graduate School of Medicine, Maebashi, Japan. 4. Integrative Center of General Surgery, Gunma University Hospital, Maebashi, Japan. 5. Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Japan. 6. Department of Oncology Clinical Development, Gunma University, Graduate School of Medicine, Maebashi, Japan. 7. Big Data Center for Integrative Analysis, Gunma University Initiative for Advance Research (GIAR), Maebashi, Japan.
Abstract
BACKGROUND AND OBJECTIVES: The Caspase14 (CASP14) was reported that the low expression of CASP14 in ovarian cancer and colon cancer was associated with cancer progression, on the other hand, that the CASP14 expression in breast cancer was higher than that of non-cancerous tissues. The purpose of this study is to determine the clinical significance of CASP14 in breast cancer. METHODS: We performed immunohistochemistry for CASP14, ER, PgR, HER2, Ki67, EGFR, CK5/6, CD44, CD24, ALDH1, claudins, and androgen receptor in 222 breast cancer patients including 55 TNBC cases, and evaluated the relationship of CASP14, above-mentioned markers, and prognosis. Using public microarray database of breast cancer, the prognostic value of CASP14 was calculated. RESULTS: High CASP14 expression was significantly associated with TNBC subtype (P = 0.015), nuclear grade (P = 0.006), Ki67, EGFR (P < 0.001, P = 0.016), ALDH1, CD44 and CD24 (P < 0.001, P < 0.001, P = 0.001) in 222 breast cancer cases, and the high expression of claudin1 (P = 0.017), and androgen receptor (P = 0.002) in TNBC cases was related to the high CASP14. According to the public database, survival in the high CASP14 breast cancer patients was shorter than low CASP14 patients. CONCLUSIONS: High CASP14 expression is a marker of breast cancer aggressiveness in association with proliferation, TNBC phenotype, and cancer stemness.
BACKGROUND AND OBJECTIVES: The Caspase14 (CASP14) was reported that the low expression of CASP14 in ovarian cancer and colon cancer was associated with cancer progression, on the other hand, that the CASP14 expression in breast cancer was higher than that of non-cancerous tissues. The purpose of this study is to determine the clinical significance of CASP14 in breast cancer. METHODS: We performed immunohistochemistry for CASP14, ER, PgR, HER2, Ki67, EGFR, CK5/6, CD44, CD24, ALDH1, claudins, and androgen receptor in 222 breast cancerpatients including 55 TNBC cases, and evaluated the relationship of CASP14, above-mentioned markers, and prognosis. Using public microarray database of breast cancer, the prognostic value of CASP14 was calculated. RESULTS: High CASP14 expression was significantly associated with TNBC subtype (P = 0.015), nuclear grade (P = 0.006), Ki67, EGFR (P < 0.001, P = 0.016), ALDH1, CD44 and CD24 (P < 0.001, P < 0.001, P = 0.001) in 222 breast cancer cases, and the high expression of claudin1 (P = 0.017), and androgen receptor (P = 0.002) in TNBC cases was related to the high CASP14. According to the public database, survival in the high CASP14breast cancerpatients was shorter than low CASP14patients. CONCLUSIONS: High CASP14 expression is a marker of breast cancer aggressiveness in association with proliferation, TNBC phenotype, and cancer stemness.
Authors: Haiming Huang; Jialin Du; Bo Jin; Lu Pang; Nan Duan; Chenwei Huang; Jiayin Hou; Wei Yu; Han Hao; Haixia Li Journal: Front Oncol Date: 2021-04-27 Impact factor: 6.244
Authors: I Chae Ye; Elana J Fertig; Josh W DiGiacomo; Michael Considine; Inês Godet; Daniele M Gilkes Journal: Mol Cancer Res Date: 2018-07-23 Impact factor: 5.852